Medicine & Life Sciences
Proteomics
100%
JNJ-61186372
73%
Neuroblastoma
61%
Estrogen Receptor Modulators
57%
osimertinib
49%
Receptor, Fibroblast Growth Factor, Type 2
46%
tropomyosin kinase
46%
Bispecific Antibodies
43%
Breast Neoplasms
43%
Phosphotyrosine
42%
Anaplastic Lymphoma Kinase
41%
Canertinib
41%
Insulin Receptor Substrate Proteins
40%
Fibroblast Growth Factor Receptors
40%
Fulvestrant
37%
Ewing's Sarcoma
37%
Triple Negative Breast Neoplasms
37%
Preclinical Drug Evaluations
36%
Estrogen Receptor alpha
36%
Ubiquitin-Protein Ligases
35%
Growth
34%
ErbB Receptors
33%
Nerve Growth Factor
33%
Embryonic Stem Cells
33%
Heterografts
30%
Glioblastoma
30%
Erlotinib Hydrochloride
29%
Consensus
29%
Neoplasms
29%
Endoderm
26%
Cell Survival
25%
Cell Differentiation
25%
Transcription Factors
24%
Tyrosine
24%
Mass Spectrometry
24%
Estrogen Receptors
23%
Phosphorylation
23%
Pharmacokinetics
23%
Therapeutics
22%
Pharmaceutical Preparations
22%
Whole Exome Sequencing
22%
RNA Sequence Analysis
20%
Protein-Tyrosine Kinases
19%
Mutation
19%
Phosphatidylinositol 3-Kinases
18%
Proteins
18%
midostaurin
17%
EWS-FLI fusion protein
16%
Tamoxifen
16%
Chemical Compounds
Oncogenic
78%
Tyrosine Kinase Inhibitor
34%
Insulin Derivative
31%
Cell Viability
30%
Tyrosine
30%
Mutation
26%
Erlotinib
24%
Pharmacokinetics
23%
Protein
20%
Tyrosine Residue
17%
Drug
16%